UK’s NICE Says Alzheimer’s Disease Drug Kisunla Is Not Cost-Effective
Forbes Healthcare
NOVEMBER 2, 2024
The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness watchdog, NICE, said the drug isn't cost-effective.
Let's personalize your content